Compare · ILMN vs TXG
ILMN vs TXG
Side-by-side comparison of Illumina Inc. (ILMN) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- ILMN operates in Health Care, while TXG operates in Industrials - the two are in different parts of the market.
- ILMN is the larger of the two at $32.26B, about 4.0x TXG ($8.14B).
- Over the past year, ILMN is up 113.0% and TXG is up 356.3% - TXG leads by 243.3 points.
- TXG has been more active in the news (13 items in the past 4 weeks vs 8 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Illumina Inc.
- 10x Genomics Inc.
- Price
- $208.37-2.48%
- $61.04-2.16%
- Market cap
- $32.26B
- $8.14B
- 1M return
- +5.11%
- +29.95%
- 1Y return
- +112.97%
- +356.28%
- Industry
- Medical Specialities
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2019
- News (4w)
- 8
- 13
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest ILMN
- Director Meister Keith A. sold $85,241,664 worth of shares (375,941 units at $226.74) (SEC Form 4)
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest TXG
- RBC Capital Mkts initiated coverage on 10x Genomics with a new price target
- Chief Executive Officer Saxonov Serge sold $667,901 worth of shares (10,486 units at $63.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 1,075,349 units (SEC Form 4)
- 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
- Chief Executive Officer Saxonov Serge sold $1,168,775 worth of shares (18,545 units at $63.02), decreasing direct ownership by 2% to 1,085,835 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Taich Adam sold $1,081,853 worth of shares (17,166 units at $63.02), decreasing direct ownership by 5% to 362,732 units (SEC Form 4) to cover withholding tax
- Officer Hindson Benjamin J. sold $870,860 worth of shares (13,818 units at $63.02), decreasing direct ownership by 3% to 488,182 units (SEC Form 4) (withholding obligation)
- Director Suliman Shehnaaz sold $140,478 worth of shares (2,207 units at $63.65) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 29,515 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge gifted 4,000 shares, decreasing direct ownership by 0.36% to 1,104,380 units (SEC Form 4)
- Director Teichmann Sarah A. sold $432,279 worth of shares (7,551 units at $57.25) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 28,058 units (SEC Form 4)